High-dimensional immune profiling

In this study, we compared changes in cell count and cell population frequencies between fresh whole blood and whole blood fixed with TokuKit over time.

In this poster, presented at the SITC Spring Scientific 2025, we used unsupervised clustering to analyze a 29M cell cytometry dataset to identify immune cell populations and subsets that correlate with response outcomes in melanoma patients treated with anti-PD1 therapy.

In this study, we compared changes in cell count and cell population frequencies between fresh whole blood and whole blood fixed with TokuKit over time.

In this study, we compared the differences between live whole blood (48 hours post blood draw) and whole blood fixed with Teiko’s 2-step whole blood collection kit, the TokuKit.

In this study, we investigated the effects of sample fixation and storage at -80C on immune cell composition and activation status by profiling whole blood samples using a 20+ marker flow cytometry panel.

In this study, we compared the differences between fresh whole blood analysis versus rapid on-site fixation, utilizing Teiko’s TokuKit. Whole blood from three healthy donors was divided into two aliquots — one for live processing, and the other for fixation.

In this study, we used 68 PBMC samples from melanoma patients to assess the effectiveness of two batch normalization tools, CytoNorm and cyCombine.

Drs. Kovacsovics-Bankowski (Huntsman Cancer Institute) & Sweere (Teiko Bio) presented at SMR 2023 on peripheral immune features associated with severe immune-related adverse events and clinical benefit in melanoma patients treated with checkpoint inhibitor.

In this abstract published as part of ASCO 2023, McAdams & Medina et al. present data on immune signatures of clinical activity in patients with advanced NSCLC treated with bintrafusp alfa, a bifunctional anti-PDL1 / TGF-beta trap.

Teiko scientists Drs. Healy & Sweere presented at AACR 2023 on immune features of immune-related adverse events and anti-PD1 response in blood in patients with urothelial carcinoma. These data were generated through a collaboration between the Parker Institute for Cancer Immunotherapy and Teiko Bio.

Drs. Healy (Teiko Bio) & Kovacsovics-Bankowski (Huntsman Cancer Institute) presented at SITC 2022 on immune signatures of severe immune-related adverse events in blood in patients with advanced melanoma treated with immunotherapy. This data was generated through a collaboration between Dr. Siwen Hu-Lieskovan of the Huntsman Cancer Institute and Teiko Bio.

Burnett, Okholm, & Tenvooren, et al. use immune profiling by mass cytometry to identify an immune trajectory associated with COVID recovery and immune subsets associated with a requirement for mechanical ventilation

Levine & Hiam-Galvez et al. use mass cytometry to profile metabolic states of early-activated CD8 T cells during infection and non-Hodkins lymphoma.

Allen & Hiam et al. use mass cytometry to define changes in immune cell frequencies and states across five tissue types in eight different mouse tumor models.

Hartmann et al. describes the development and utilization of a comprehensive and easily customizable 33-marker mass cytometry panel optimized for immune monitoring of clinical trials.

In this seminal Cell 2017 publication, Spitzer, Carmi & Reticker-Flynn et al. show that effective immunotherapy treatment requires peripheral immune cell engagement in both breast and colon cancer mouse models.

Rahim, Okholm, & Jones et al. show that immune checkpoint blockade activates CD8 T cell differentiation and proliferation in the lymph node, not within the tumor microenvironment, and these cells can be detected in transit via blood profiling.

Martin et al. use single cell sequencing validated by mass cytometry to identify a 4-subset signature for predictive scoring of response to anti-TNF treatment among patients with ileal Crohn’s disease.

Prokopi et al. use mass cytometry to track dendritic cell and T cell subsets in both the tumor and tumor-draining lymph nodes and identify distinct patterns of migration and recruitment throughout melanoma progression and treatment.

Rochigneux et al. identify new blood-based candidate immune cell biomarkers associated with successful clinical outcomes to anti-PD-1 therapy for a subset of NSCLC patients in the KEYNOTE-001 trial.

Using mass cytometry, Good et al. profiled post-infusion CAR T cells in patients with large B cell lymphoma and identified a novel population of CAR Tregs associated with disease progression and decreased neurotoxicity.

Using mass cytometry, Wagner et al. profile 73 proteins across nearly 200 samples of breast tumor and adjacent non-tumor tissue to identify novel features of tumor composition linked to poor prognosis.

Kleftogiannis et al. developed a machine learning framework using mass cytometry data from 45 leukemia patients and identified predictive biomarkers of survival

Kosoy et al. profiled immune composition of nearly 1200 patients with IBD and over 300 controls using mass cytometry and identified key immune subsets target by combination therapy.

In Guo et al., the team used mass cytometry in combination with RNA and TCR sequencing to validate two unique clusters of regulatory T cells (Treg) that respond differently to injury.

The team Simonds, Lu, & Badillo et al. used mass cytometry determine why glioblastoma, the most common malignant brain tumor, is also the most resistant to immunotherapy.